STOCK TITAN

TC BioPharm (Holdings) plc - TCBP STOCK NEWS

Welcome to our dedicated news page for TC BioPharm (Holdings) plc (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TC BioPharm (Holdings) plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TC BioPharm (Holdings) plc's position in the market.

Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) CEO Bryan Kobel featured on 'The Big Biz Show' to discuss recent developments in the company's allogeneic gamma-delta T cell therapies for cancer and other indications. The interview will be broadcasted on various platforms, including cable TV, streaming services, and radio in 175 countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) to host a shareholder update call on March 5th, 2024, discussing operations, clinical trials, 2024 outlook, and business development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none
-
News
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) announces a shareholder update call on March 5th, 2024, to discuss operations, clinical trials, 2024 outlook, and business development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) receives MHRA clearance for dosing size increase and outpatient treatment in ACHIEVE trial for TCB-008 in Acute Myeloid Leukemia. The amendment allows for a dose increase to 12x10^7-23x10^7 gamma delta t-cells and patients to be treated as outpatients, impacting trial timing and FDA trial plans positively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.93%
Tags
none
-
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) CEO and Process Development Manager to Speak at 7th CAR-TCR Summit Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences
-
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP) announces shareholder update with projected outlook for 2024, highlighting $11.6M cost savings, FDA clearance for Phase 1B study in AML, collaborations, and milestone achievements. The Company filed a preliminary proxy statement for potential shareholder approval of issuing shares for non-public offerings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.05%
Tags
none
Rhea-AI Summary
TC BioPharm (TCBP) CEO Bryan Kobel featured in live interview with 'Big Biz Show' to discuss the company's allogeneic gamma-delta T cell therapies for cancer. The interview will be aired on cable TV, streaming services, and radio in 175 countries, with podcasts available on various platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.38%
Tags
none
-
Rhea-AI Summary
TC BioPharm (Holdings) PLC, a clinical stage biotechnology company, is set to participate in the Sequire Investor Summit 2024. The company's CEO will conduct in-person one-on-one meetings and deliver a presentation on January 24 at 1:30 PM ET. TC BioPharm is focused on developing allogeneic gamma-delta T cell therapies for cancer and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
conferences
-
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market after its common shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
Rhea-AI Summary
TC BioPharm (Holdings) PLC (NASDAQ: TCBP) is implementing cost-saving measures to reduce cash burn by approximately 50% and extend its financial runway, with a focus on advancing its lead therapeutic to the nearest data inflection point, specifically the ACHIEVE trial interim review. The company plans to scale down research and development, implement a focused manufacturing platform, and streamline its organization, resulting in a reduction of headcount by approximately 50%. These initiatives are aimed at driving efficiency and prioritizing clinical success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.2%
Tags
none
TC BioPharm (Holdings) plc

Nasdaq:TCBP

TCBP Rankings

TCBP Stock Data

3.23M
4.60M
0.14%
10.24%
8.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
Motherwell